Zimmer Biomet Holdings, Inc. (ZBH)
Zimmer Biomet is a global medical technology company that designs and manufactures artificial joints and surgical tools to help people move and live better.
Is Zimmer Biomet Holdings, Inc. a good stock for a UK beginner?
The honest version: Zimmer Biomet is a global medical technology company that designs and manufactures artificial joints and surgical tools to help people move and live better.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Widespread adoption of digital health and AI-driven surgical tools.
Significant changes to healthcare reimbursement policies.
What does Zimmer Biomet Holdings, Inc. do?
Zimmer Biomet specialises in orthopaedic implants, such as artificial knees and hips, which are used by surgeons to replace worn-out joints. They make their money by selling these high-tech medical devices and the surgical equipment needed to install them to hospitals and clinics worldwide. Much rides on how well they manage the rising demand for joint replacements as the global population gets older.
On our factor screen it looks strongest on value and income, and weakest on quality.
- ✓Pays a dividend - about 1.0% a year
- ✓Growing - revenue up about 9% over the year
- Value screens high (75/100)
- High gross margins indicate strong pricing power for their medical devices.
- The ageing global population provides a reliable, long-term source of demand.
- Low beta suggests the stock may be more stable than the broader market during turbulent times.
- Changes in government healthcare funding could reduce the number of surgeries performed.
- Reliance on hospital budgets means economic downturns can lead to delayed elective procedures.
- Rapid technological change could make existing product lines obsolete.
What do Zimmer Biomet Holdings, Inc.'s numbers mean?
How much money does Zimmer Biomet Holdings, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Zimmer Biomet Holdings, Inc. pay a dividend?
Yes - Zimmer Biomet Holdings, Inc. currently pays a dividend of about 1.0% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
When does Zimmer Biomet Holdings, Inc. report earnings, and how did recent quarters go?
Zimmer Biomet Holdings, Inc. is next scheduled to report on about 2026-08-05 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-04-28 | $1.86 | $2.09 | Beat +12% |
| 2026-02-10 | $2.40 | $2.42 | In line |
| 2025-11-05 | $1.87 | $1.90 | Beat +2% |
| 2025-08-07 | $1.98 | $2.07 | Beat +5% |
| 2025-05-05 | $1.77 | $1.81 | Beat +2% |
| 2025-02-06 | $2.29 | $2.31 | In line |
Across the last 6 quarters here, Zimmer Biomet Holdings, Inc. came in ahead of what analysts expected 4 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.
Agilent Technologies, Inc.What are the scenarios for Zimmer Biomet Holdings, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Zimmer Biomet Holdings, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High gross margins indicate strong pricing power for their medical devices.
- The ageing global population provides a reliable, long-term source of demand.
- Low beta suggests the stock may be more stable than the broader market during turbulent times.
- Net margins are relatively modest compared to the high gross margins, suggesting high operating costs.
- Return on equity is quite low, which may indicate inefficient use of shareholder capital.
- The company operates in a highly regulated industry where product recalls or safety issues can be costly.
- Changes in government healthcare funding could reduce the number of surgeries performed.
- Reliance on hospital budgets means economic downturns can lead to delayed elective procedures.
- Rapid technological change could make existing product lines obsolete.
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained decline in the number of elective surgeries performed globally.
- A major regulatory change that significantly lowers the price hospitals are willing to pay for implants.
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.